Liver

Latest Articles

Hepatitis D: Recent Advances in Virology, Immunology and Treatment

By

Vincent Soreca

Forty years after the emergence of HDV, the first anti-HDV therapeutic has been approved by the EMA, indicating the dawn of a new era for this difficult to treat disease

Effects of Short vs Standard Course Sofosbuvir-Velpatasvir in Patients With HCV

By

Bradley van Paridon

In this phase 4 non-inferiority trial, researchers compared the effects of short course vs standard course therapy with sofosbuvir-velpatasvir for the treatment of patients with hepatitis C virus.

Phase 1 Trial Data Support Safety, Efficacy of Novel HBV Treatment

By

Emily Pond

Investigators assessed the safety profile and antiviral activity of the agent RO7049389 for the treatment of chronic hepatitis B virus infection.

Drug-Induced Hepatotoxicity Ends Development of Novel HBV Therapy

By

Brian Park, PharmD

The phase 2 trial was evaluating the effects of ABI-H2158 in 88 treatment-naïve patients with HBeAg positive or HBeAg negative chronic hepatitis B infection without cirrhosis.

Pharmacotherapies for Liver Fibrosis, NASH Resolution Ranked

By

Cassandra Pardini, PharmD

Although NASH is a common cause of chronic liver disease, there is limited evidence surrounding its management.

Increasing Concerns Surrounding Prevalence of Infections in Cirrhosis

By

Rita Aghjayan

The natural history of cirrhosis is significantly affected by the increasing prevalence of infections, with strategies for prevention and treatment difficult to compose.

Cholestatic Injury Associated With Biliary Tract Inflammation May Be a Late Complication of Severe COVID-19

By

Rita Aghjayan

Investigators described a syndrome of cholangiopathy in patients recovering from severe COVID-19 with abnormal liver tests and bile duct injury.

Survival Rates Lower for Black Liver Transplant Recipients

Black recipients of liver transplants (LTs) have lower survival compared with Whites or Hispanics.

SARS-CoV-2 Outcomes in Patients With Chronic Liver Disease

By

Jennifer Champagne, PharmD, RPh, BCPS

Investigators assessed the outcomes of SARS-CoV-2 positivity in patients with chronic liver diseases and cirrhosis.

Telemonitoring-Supported Exercise Training May Improve Liver Inflammation, Fibrosis in MetS

By

Rita Aghjayan

Investigators assessed the effects of an exercise program with telemonitoring-based supervision on liver inflammation and risk for metabolic-associated fatty liver disease.

Hospitalization Trends in Comorbid CLDs, SUDs

By

Rita Aghjayan

Investigators aimed to describe trends in hospitalization among patients with comorbid chronic liver diseases and substance use disorders.

Meta-Analysis and Evidence Based Management of HCC

By

Bradley van Paridon

Investigators analyzed the current evidence for treatment of hepatocellular carcinoma and what factors might impact response to therapies.

LFT Abnormalities at Hospital Admission Associated With Severe SARS-CoV-2 Infection

By

Colby Stong

Investigators assessed the relationship between abnormal liver function tests and severe COVID-19 disease course.

Novel Gene Therapy for Wilson Disease Gets Fast Track Status

By

Brian Park, PharmD

VTX-801 is an investigational, novel rAAV-based gene therapy that delivers a shortened version of the ATP7B transgene.

Prevalence of Cardiac-Specific Mortality in Major GI Cancers

By

Rita Aghjayan

Investigators assessed the cardiac-specific mortality rate among patients with major GI cancers, as well as the relationship between radiation and chemotherapy with survival outcomes.

TraP HepC: A Nation-Wide, Multidisciplinary Program Aimed At Eliminating the Public Health Threat of HCV Infections

By

Jessica Nye, PhD

Investigators reported on the hepatitis C virus cascade of care throughout the first few years of a treatment-as-prevention program initiated in Iceland.

Toxic Dust Exposure Tied to Liver Disease in WTC Responders

Early arrival at the site after the attack on Sept. 11, 2001, is associated with an increased risk for hepatic steatosis among World Trade Center responders.

New Vial Sizes for Bivigam, Nabi-HB Now Available

By

Brian Park, PharmD

The new vial sizes are currently in stock and commercially available in the US.

COVID-19’s Continuing Toll: Increased Alcohol Use and Liver Disease Among Women

By

Tori Rodriguez, MA, LPC, AHC

To discuss the potential factors driving the increasing alcohol use among women as well as potential solutions, we interviewed David Streem, MD, and Leena P. Mittal, MD, FACLP.

A Definition of Textbook Outcome in Liver Surgery

By

Bradley van Paridon

Investigators attempted to reach international agreement on the definition of textbook outcome in liver surgery and to assess occurrence of this outcome following liver resection.